Trial Profile
In methotrexate resistant rheumatoid arthritis, switching methotrexate to tofacitinib versus adding tofacitinib to methotrexate, open labeled, multicenter randomized non-inferiority study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RAXEL
- 20 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 08 May 2017 Planned End Date changed from 18 May 2017 to 18 May 2019.